BiotechTube
Moleculent

Moleculent

Stockholm, Sweden· Est.
moleculent.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18M

Overview

Moleculent is a private, pre-revenue platform company developing technology to map and analyze cell-cell communication in human tissue. Its core focus is on high-plex analysis of receptor-ligand interactions within the tissue context, aiming to provide unprecedented insights into disease mechanisms, particularly in immunology and oncology. The company is backed by notable venture capital firms and is positioning its platform as a tool to enable more effective drug development and personalized treatment strategies.

OncologyImmunology

Technology Platform

Platform for mapping high-plex cell-cell communication by analyzing receptor-ligand interactions within the native tissue context to provide a functional understanding of biology.

Funding History

2
Total raised:$18M
Series A$12.8M
Seed$5.2M

Opportunities

The growing demand for advanced tools in immuno-oncology and personalized medicine presents a major opportunity.
The platform's ability to decipher drug mechanisms of action and patient response could make it a critical tool for pharmaceutical R&D and companion diagnostic development.

Risk Factors

The company faces intense competition in the spatial biology market and must successfully translate its technology into a reliable, adopted platform.
As a private, early-stage company, it also carries significant execution, commercialization, and funding risks.

Competitive Landscape

Moleculent competes in the rapidly expanding spatial biology and multi-omics market, which includes companies like 10x Genomics (Visium, Xenium), NanoString (GeoMx, CosMx), Akoya Biosciences, and Vizgen. Its differentiation hinges on a specific focus on high-plex, functional analysis of cell-cell communication networks.

More companies in Synthetic Biology →More companies in Sweden →